BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS
申请人:Bayer Pharma Aktiengesellschaft
公开号:US20170121322A1
公开(公告)日:2017-05-04
The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory 3,4-dihydropyrido[2,3-b]pyrazinones with a meta-substituted aromatic amino or ether group of the general formula (I)
in which A, X, Y, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and n are each as defined in the description, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of tumour disorders.
Furthermore, this invention relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
本发明涉及一种具有通式(I)中的meta-取代芳香氨基或醚基的BET蛋白抑制剂,特别是BRD4抑制剂的3,4-二氢吡啶并[2,3-b]吡嗪酮,其中A、X、Y、R1、R2、R3、R4、R5、R6和n如描述中所定义,以及包含根据本发明的化合物的药物组合物,并在高增殖疾病的情况下,特别是在肿瘤疾病的情况下的预防和治疗中的使用。此外,本发明还涉及在病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制中使用BET蛋白抑制剂。